Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA599584
Max Phase: Preclinical
Molecular Formula: C16H14O4
Molecular Weight: 270.28
Molecule Type: Small molecule
Associated Items:
ID: ALA599584
Max Phase: Preclinical
Molecular Formula: C16H14O4
Molecular Weight: 270.28
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
Standard InChI: InChI=1S/C16H14O4/c1-11(17)20-16-6-4-12(5-7-16)2-3-13-8-14(18)10-15(19)9-13/h2-10,18-19H,1H3/b3-2+
Standard InChI Key: MEMZFJTYLFBJEC-NSCUHMNNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 270.28 | Molecular Weight (Monoisotopic): 270.0892 | AlogP: 3.19 | #Rotatable Bonds: 3 |
Polar Surface Area: 66.76 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.66 | CX Basic pKa: | CX LogP: 3.31 | CX LogD: 3.29 |
Aromatic Rings: 2 | Heavy Atoms: 20 | QED Weighted: 0.51 | Np Likeness Score: 0.65 |
1. Wong Y, Osmond G, Brewer KI, Tyler DS, Andrus MB.. (2010) Synthesis of 4'-ester analogs of resveratrol and their evaluation in malignant melanoma and pancreatic cell lines., 20 (3): [PMID:20022501] [10.1016/j.bmcl.2009.12.006] |
2. Acerson MJ, Fabick KM, Wong Y, Blake C, Lephart ED, Andrus MB.. (2013) A new synthesis of 4'-resveratrol esters and evaluation of the potential for anti-depressant activity., 23 (10): [PMID:23582778] [10.1016/j.bmcl.2013.03.046] |
3. Lephart ED, Acerson MJ, Andrus MB.. (2016) Synthesis and skin gene analysis of 4'-acetoxy-resveratrol (4AR), therapeutic potential for dermal applications., 26 (14): [PMID:27265258] [10.1016/j.bmcl.2016.05.068] |
4. Uzura S, Sekine-Suzuki E, Nakanishi I, Sonoda M, Tanimori S.. (2016) A facile and rapid access to resveratrol derivatives and their radioprotective activity., 26 (16): [PMID:27426305] [10.1016/j.bmcl.2016.07.018] |
Source(1):